Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Zymeworks ( (ZYME) ) just unveiled an update.
Zymeworks announced promising preliminary results from its Phase 1 trial of ZW191, an antibody-drug conjugate targeting folate receptor-alpha, at the AACR-NCI-EORTC Conference. The study showed a 64% overall response rate in gynecological cancers at doses of 6.4mg/kg and above, with a manageable safety profile, indicating potential for ZW191 in treating advanced solid tumors. The company plans to initiate dose optimization in ovarian cancer by the fourth quarter of 2025, aiming to further evaluate clinical activity and safety, which could enhance its positioning in the cancer treatment market.
The most recent analyst rating on (ZYME) stock is a Hold with a $15.00 price target. To see the full list of analyst forecasts on Zymeworks stock, see the ZYME Stock Forecast page.
Spark’s Take on ZYME Stock
According to Spark, TipRanks’ AI Analyst, ZYME is a Neutral.
Zymeworks’ strong revenue growth and positive earnings call sentiment are offset by profitability challenges and cash flow issues. The technical analysis shows a bullish trend, but valuation remains a concern due to negative earnings.
To see Spark’s full report on ZYME stock, click here.
More about Zymeworks
Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics aimed at improving the standard of care for challenging diseases such as cancer, inflammation, and autoimmune disorders.
Average Trading Volume: 552,970
Technical Sentiment Signal: Buy
Current Market Cap: $1.36B
For a thorough assessment of ZYME stock, go to TipRanks’ Stock Analysis page.